In contrast, a recent post hoc analysis from the DECLARE-TIMI 58 trial showed that dapagliflozin reduced the incidence of AF in patients with T2DM.9 In addition, Ling et al. 24 found that SGLT2is were related to a lower incidence of new-onset AF than DPP-4 inhibitors. This evidence concerns the gene DPP4 and atrial fibrillation.